HSA Reclassified Drug | Exemptions For Supply of Ranitidine Without Prescription

Criteria

Eligible Active Ingredient: Ranitidine. As an oral preparation
With Effective From: 17-Jan-2000
Indication Permitted: Short-term relief of heartburn, dyspepsia and hyperacidity.
Maximum Daily Dose: 300mg
Maximum Supply per Transaction: 14 days
Minimum Age of User:
Patient Information Leaflet from HSA/PSS: Download PIL (Link to HSA website)

Mechanism of Action of Ranitidine

The H2 antagonists are competitive inhibitors of histamine at the parietal cell H2 receptor. They suppress the normal secretion of acid by parietal cells and the meal-stimulated secretion of acid. They accomplish this by two mechanisms: histamine released by ECL cells in the stomach is blocked from binding on parietal cell H2 receptors which stimulate acid secretion, and other substances that promote acid secretion (such as gastrin and acetylcholine) have a reduced effect on parietal cells when the H2 receptors are blocked.

Additional Information of Ranitidine

Pharmacology Class: Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)
Therapeutic Class: Drugs For Acid Related Disorders
Chemical Class: H2-Receptor Antagonists
Synonyms: RAN | Ranitidina | Ranitidinum

Show All HSA-registered therapeutic products granted exemption to supply without prescription

References

  1. Health Science Authority of Singapore – Reclassified POM
  2. Drugbank

HSA-Registered Products Containing Ranitidine As an oral preparation

wpDataTable with provided ID not found!

This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.